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Foxp3+ regulatory T (Treg) cells can undergo reprog-
ramming into a phenotype expressing proinflamma-
tory cytokines. However, the biologic significance
of this conversion remains unclear. We show that
large numbers of Treg cells undergo rapid reprog-
ramming into activated T helper cells after vaccina-
tion with antigen plus Toll-like receptor 9 (TLR-9)
ligand. Helper activity from converted Treg cells
proved essential during initial priming of CD8+
T cells to a new cross-presented antigen. Help from
Treg cells was dependent on CD40L, and (unlike
help from conventional non-Treg CD4+ cells) did
not require preactivation or prior exposure to
antigen. In hosts with established tumors, Treg cell
reprogramming was suppressed by tumor-induced
indoleamine 2,3-dioxygenase (IDO) and vaccination
failed because of lack of help. Treg cell reprogram-
ming, vaccine efficacy, and antitumor CD8+ T cell
responses were restored by pharmacologic inhibi-
tion of IDO. Reprogrammed Treg cells can thus
participate as previously unrecognized drivers of
certain early CD8+ T cell responses.
INTRODUCTION
Foxp3+ regulatory T (Treg) cells are a unique cell population.
They are a critical component of normal self-tolerance, yet, para-
doxically, in some settings the Treg cell lineage is required in
order to support the early phase of normal immune responses
(Lund et al., 2008). It has been unclear how Treg cells could
both suppress and promote immune responses in different
contexts (Zhou et al., 2009a).
Recently, it has been observed that Treg cells retain an unex-
pected degree of phenotypic plasticity. Under certain condi-
tions, Treg cells may lose their suppressor phenotype and
become ‘‘reprogrammed’’ into T helper-like cells (Sharma
et al., 2009; Yang et al., 2008; Zhou et al., 2009b). Phenotypi-942 Immunity 33, 942–954, December 22, 2010 ª2010 Elsevier Inc.cally, these former Treg cells resemble proinflammatory effector
cells (Duarte et al., 2009; Williams and Rudensky, 2007), and
large numbers of such cells may be found in mice dying of infec-
tion, in chronic autoimmune disorders, or in mice rejecting tissue
allografts (Oldenhove et al., 2009; Vokaer et al., 2010; Zhou et al.,
2009b). However, these are all highly abnormal conditions, and it
has been unclear whether reprogrammed Treg cells play a phys-
iologic role in normal, protective immune responses.
We have shown that Treg cell reprogramming can be regu-
lated in vitro by the enzyme indoleamine 2,3-dioxygenase
(IDO). IDO is an innate immunoregulatory mechanism that partic-
ipates in tolerance and immunosuppression in pregnancy,
mucosal tolerance, and other settings (Mellor and Munn,
2008). Hosts with established tumors can show markedly
elevated levels of IDO in tumor-draining lymph nodes (Munn
et al., 2004), and tumor-induced IDO can directly activate
Foxp3+ Treg cells for enhanced suppressor activity (Sharma
et al., 2007). Conversely, if IDO is blocked (e.g., by the pharma-
cologic IDO-inhibitor 1-methyl-tryptophan), then the Treg cells in
tumor-bearing hosts become unstable and can be driven by
inflammation to undergo reprogramming into helper-like
T cells, expressing IL-17 and other proinflammatory cytokines
(Sharma et al., 2009). However, it has been unclear whether
these phenotypically reprogrammed Treg cells play any func-
tional role in antitumor immunity.
In the current study, we now show that cells of the Foxp3+
lineage can participate as an integral part of the CD4+ T helper
system. In certain settings, reprogrammed Treg cells were found
to play an indispensable helper role, allowing innate inflamma-
tion to drive the early (priming) phase of CD8+ T cell response
to new antigen. Further, we show that in mice with established
tumors, one key reason for the failure of therapeutic immuniza-
tion can be the inhibition of normal Treg cell reprogramming by
tumor-induced IDO.RESULTS
TregCells UndergoReprogramming in Vaccine-Draining
Lymph Nodes
Treg cell reprogramming was studied by means of vaccination
with a whole-protein antigen (chicken ovalbumin, OVA), which
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to CD8+ T cells. In this cross-presentation model, the CD8+ T cell
response is heavily dependent on CD4+ help to ‘‘license’’ the
DCs (Bennett et al., 1998). Vaccinations were performed in
C57BL/6 mice bearing a Foxp3-GFP fusion protein targeted to
the Foxp3 locus (Fontenot et al., 2005). We have previously
shown that Treg cells from these mice display detectable GFP
fluorescence for at least 4 days after reprogramming (Sharma
et al., 2009). Foxp3GFP mice received adoptive transfer of
OVA-specific OT-I cells (CD8+, recognizing the SIINFEKL
peptide of OVA), followed by immunization with whole OVA
protein plus the TLR9-ligand CpG-1826, emulsified in incom-
plete Freund’s adjuvant (IFA).
Figure 1A shows analysis of CD4+ cells in vaccine-draining
lymph nodes (LNs) after immunization. Treg cells and conven-
tional (non-Treg) CD4+ cells were distinguished based on
Foxp3-GFP expression. Treg cells are known to respond rapidly
to proinflammatory signals (O’Gorman et al., 2009); based on
these reports, we analyzed activation-induced phosphorylation
of STAT5. As early as 6 hr after immunization, large numbers of
Treg cells (GFP+) expressed phosphorylated STAT5, whereas
non-Treg CD4+ cells (GFP) did not respond until 24–48 hr after
immunization. Similar results were seen with the early activation
marker CD69 (Figure 1A, bottom). Thus, in this model, Treg cells
were the first and most rapid responders to vaccine-induced
activation.
We next asked whether activated Treg cells showed evidence
of phenotypic plasticity (reprogramming) after vaccination. One
defining characteristic of such plasticity is that reprogrammed
Treg cells acquire the ability to express proinflammatory cyto-
kines (IL-2, IL-17, TNFa) when restimulated in vitro with PMA
plus ionomycin (Sharma et al., 2009; Yang et al., 2008). Expres-
sion of these cytokines implies a major alteration in the Treg cell
phenotype, because they would normally be profoundly
suppressed in the Foxp3+ lineage (Williams and Rudensky,
2007). For all in vitro restimulation studies, we used a low
concentration of PMA+ionomycin (as described in Supplemental
Experimental Procedures available online) in order to minimize
the nonspecific induction of cytokine expression resulting from
the in vitro stimulation alone. Under these conditions, Figure 1B
shows that prior to vaccination, resting Treg cells from Foxp3GFP
mice produced no IL-2 or TNFa when challenged with PMA
(Figure 1B, left). However, after vaccination (Figure 1B, right)
many Treg cells had acquired the ability to produce IL-2 and
TNFa, and large numbers also coexpressed IL-17, suggesting
acquisition of a polyfunctional ‘‘helper-like’’ phenotype.
The expression of proinflammatory cytokines suggested that
Foxp3 was no longer fully suppressing these genes. In some
reports, Treg cells undergoing reprogramming in vitro may lose
Foxp3 expression, although in other cases the reprogrammed
Treg cells can maintain their expression of Foxp3 (Yang et al.,
2008). In our system, Treg cells that underwent vaccine-induced
reprogramming in vivo continued to express the Foxp3-GFP
reporter protein throughout the experiment (>4 days), as shown
in Figure 1A. As a technical caveat, however, Figure S1A shows
that, after reprogramming, the Foxp3 protein became difficult to
detect by the usual intracellular staining methods, suggesting
that Foxp3 might become sequestered or otherwise altered in
its subcellular location (although it remained readily detectableIby GFP fluorescence and immunoblot; Figure S1B). Thus, for
our purposes, the Foxp3-GFP reporter mice provided the most
reliable marker to identify reprogrammed Treg cells.
Reprogrammed Treg Cells Upregulate Cell-Surface
CD40 Ligand
We next examined the in vivo induction of cell-surface CD40-
ligand expression on Treg cells. CD40L is an important functional
mediator of T cell help (Bennett et al., 1998; Schoenberger et al.,
1998), and it could be measured directly ex vivo, without
requiring in vitro stimulation. Figure 1C shows that CD40L was
upregulated on a subset of Treg cells beginning at approximately
15 hr after vaccination. Of note, under our experimental
conditions, the only cells expressing CD40L at these early time
points derived exclusively from the Treg cell population (GFP+).
Somewhat fewer Treg cells expressed CD40L than could be
induced to express cytokines with PMA, but up to 25% of all
Treg cells upregulated CD40L. Additional studies, not shown,
confirmed that CD40L was expressed specifically on the subset
of reprogrammed Treg cells that also coexpressed proinflamma-
tory cytokines (polyfunctional phenotype). Although it is known
that some Treg cells may express inducible or intracellular
CD40L under various conditions (Taylor et al., 2001), in our
model the constitutive expression of surface CD40L appeared
an informative marker of the reprogrammed phenotype.
Results from the Foxp3GFP gene-targeted mice were
confirmed in a second reporter strain, bearing a Bac-transgenic
GFP-cre-recombinase fusion protein under the Foxp3 promoter
(Zhou et al., 2009b). When this mouse is crossed with
a ROSA26-YFP (floxed-stop) reporter strain, the F1 offspring
have >95% of Foxp3+ cells irreversibly marked by YFP (Zhou
et al., 2009b). Figure 1D shows that immunization of these mice
likewise caused phenotypic reprogramming of Treg cells (cyto-
kine expression) and constitutive upregulation of surface
CD40L. (In the analysis in Figure 1D, both the GFP and YFP
signals are combined in the green channel, such that all cells
that currently or previously expressed Foxp3 are marked; see
Figures S1C and S1D.)
Taken together, these results demonstrated that Treg cells
responded rapidly to vaccination (more rapidly than the conven-
tional, non-Treg CD4+ cells). After vaccination, many Treg cells
acquired the ability to express proinflammatory cytokines and
CD40L, suggestive of a helper T cell phenotype.
Treg Cell Reprogramming Is Driven by CpG-Induced
Inflammatory Signals
Figure 1B showed that successful reprogramming of Treg cells
required the inclusion of CpG in the vaccine. CpG is known to
inhibit the suppressor activity of Treg cells in vivo via a signaling
pathway requiring MyD88, the adaptor protein downstream of
TLR9 (Pasare and Medzhitov, 2003). Consistent with this,
Figure S1E shows that Treg cells adoptively transferred into
hosts lackingMyD88were unable to undergo normal reprogram-
ming in response to CpG vaccine. IL-6 is a key proinflammatory
cytokine downstream of MyD88 (Pasare and Medzhitov, 2003),
which is known to drive Treg cell reprogramming in vitro (Yang
et al., 2008). Figure S1E shows that Treg cells transferred into
hosts lacking IL-6 also failed to undergo normal reprogramming
in response to vaccination. Finally, Figure 1E shows that themmunity 33, 942–954, December 22, 2010 ª2010 Elsevier Inc. 943
Figure 1. Foxp3+ Treg Cells Undergo Phenotypic Reprogramming after Vaccination
(A) Foxp3GFP mice received adoptive transfer of OT-I cells and immunization with OVA+CpG+IFA vaccine. At different time points, draining LNs were stained for
phospho-STAT5 and surface CD69; graphs show the percentage of gated CD4+ Treg cells (GFP+) and non-Treg cells (GFP–) expressing the antigens at each time
point.
(B) Foxp3GFP mice received OT-I cells and were immunized as above, with or without CpG in the vaccine. Draining LN cells were harvested 4 days after vacci-
nation, incubated for 4 hr with low-dose PMA+ionomycin in the presence of brefeldin A, then stained for intracellular cytokines.
(C) Foxp3GFP mice received OT-I cells and immunization as above, and draining LNs were stained for CD40L expression at different times (staining was directly
ex vivo, without PMA treatment). Graph shows pooled data from 3–5 experiments at each time point (error bars show SD).
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CpG producing progressively more reprogramming of Treg cells
(measured in these experiments by CD40L upregulation).
Thus, the reprogramming observed in our system appeared
consistent with other examples of reprogramming reported in
the literature and was driven by the innate immune system
(TLR ligand, MyD88, and IL-6). Moreover, the degree of Treg
cell reprogramming closely tracked the ability of the vaccination
to stimulate CD8+ T cell responses (i.e., proliferation of OT-I cells,
as shown in Figure 1E). This concordance prompted us to next
ask whether reprogrammed Treg cells were providing functional
helper activity for the CD8+ T cells.
Reprogrammed Treg Cells Provide Help
for Cross-presentation
To assess the functional activity of converted Treg cells, we used
host mice with a targeted disruption of the TCRa chain (Tcra/
mice), which lack all endogenous CD4+ or CD8+ T cells. (These
mice have B cells, NK cells, and gd T cells, and so are not globally
lymphopenic, but selectively lack ab T cells.) Tcra/ hosts
received adoptive transfer of either sorted Foxp3GFP Treg cells,
sorted non-Treg cells (CD4+GFP– cells from the same mice), or
no CD4+ cells. Mice were rested, then received CFSE-labeled
OT-I cells and were immunized with OVA+CpG+IFA vaccine,
and draining LNs were analyzed 4 days later. Figure 2A shows
that Tcra/ mice receiving no CD4+ cells, or receiving only the
non-Treg cell fraction of CD4+ cells, supported little proliferation
ofOT-I cellsandnoupregulationof thedifferentiationmarkergran-
zymeB. (Also, inmany experiments, the OT-I cells that attempted
to activate in the absence of CD4 help showed a reduction in CD8
expression, as visible in Figure 2A.) In contrast, the OT-I cells in
mice receiving the Treg cell fraction showed a robust proliferative
response to vaccination and extensive upregulation of granzyme
B. Thus, in our model, it appeared that virtually all of the available
helper activity by transferred CD4+ cells was being contributed by
theTregcell fraction, not by theconventional non-TregCD4+cells.
This potent helper activity contained within the Treg cell
lineage was not an artifact of Treg cells derived from the
Foxp3GFP gene-targeted strain, because sorted CD4+CD25+
Treg cells from wild-type B6 mice produced identical results,
and sorted Treg cells from F1(Foxp3-GFP-cre 3 R26-YFP)
donors (as used in Figure 1D) were also excellent helper cells
in the Tcra/ model (data not shown).
CD40L on Reprogrammed Treg Cells Drives DC
Activation and CD8+ T Cell Proliferation
CD40L is a key molecular mechanism by which helper T cells
activate (‘‘license’’) DCs to cross-present antigens to CD8+
T cells (Bennett et al., 1998; Schoenberger et al., 1998). We
asked whether the surface CD40L expressed by reprog-
rammed Treg cells allowed them to activate host DCs. DC
activation was assessed in these experiments as upregulation
of CD80 and CD86. In Figure 2B, Tcra/ mice received Treg(D) F1(Foxp3-GFP-cre 3 ROSA26-YFP) mice received OT-I cells and immunizatio
seen in the FL1 channel.
(E) Foxp3GFP mice received CFSE-labeled OT-I cells (Thy1.1 congenic), followed
analyzed for surface CD40L; OT-I cells (gated Thy1.1+) were analyzed for CFSE
In each panel, data are representative of 3–5 experiments (17 experiments for B
Icells either from wt donors or from Cd40lg/ donors (control
mice received no Treg cells); then all mice received OT-I cells
and OVA+CpG+IFA vaccine. In Tcra/ mice receiving no Treg
cells, the DCs in vaccine-draining LNs were unable to upregu-
late CD80 and CD86 (Figure 2B, histograms), and the OT-I
cells did not divide or express granzyme B (Figure 2B, dot
plots). In contrast, in hosts receiving wt Treg cells, the DCs
expressed high levels of CD80 and CD86 after vaccination,
and OT-I cells divided robustly and upregulated granzyme B.
However, mice reconstituted with Treg cells lacking CD40L
showed no upregulation of CD80 and CD86 on DCs, and no
proliferation of OT-I cells. Figure S2A shows that upregulation
of costimulatory molecules on the CD8a+ subset of DCs
(which are the specific APCs critical for cross-presentation to
CD8+ T cells) was dependent on help from reprogrammed
Treg cells.
Thus, adoptive-transfer studies unexpectedly revealed that
virtually all of the spontaneous helper activity of resting CD4+
T cells in our system was contained in the Treg cell fraction,
not in the conventional, non-Treg CD4+ cells. In our model, in
which a new antigen must be cross-presented for the first time
to naive CD8+ T cells, it proved to be the Treg cell population
that rapidly underwent reprogramming, upregulated CD40L,
and licensed DCs for cross-presentation.Reprogrammed Treg Cells Rescue the Helper Defect
in Cd40lg–/– Hosts
Tcra/ mice are partially lymphopenic, which might influence
Treg cell reprogramming (Duarte et al., 2009). Therefore, we
confirmed these findings in a second, nonlymphopenic model.
Mice with a targeted disruption of the CD40 ligand gene
(Cd40lg/ mice) have a profound defect in antigen cross-
presentation to CD8+ T cells because of a lack of functional
CD4 help (which requires CD40L) (Bennett et al., 1998). We
asked whether CD40L-sufficient Treg cells (and only the Treg
cells) could rescue this selective T helper cell defect in
Cd40lg/mice. Treg cells and non-Treg CD4+ cells were sorted
from CD40L-sufficient Foxp3GFP donors and adoptively trans-
ferred into Cd40lg/ recipients. All mice then received
CFSE-labeled OT-I responder cells and were immunized with
OVA+CpG+IFA vaccine, as in the Tcra/ model. Figure 2D
shows that the transferred Treg cells underwent reprogramming
after vaccination, upregulated CD40L, and supplied potent help
for OT-I activation. In contrast, the non-Treg cell fraction of CD4+
cells did not upregulate CD40L or proinflammatory cytokines
after transfer and failed to provide help for OT-I cells. (Likewise,
none of the endogenous Treg cells inCd40lg/mice underwent
detectable reprogramming, which is consistent with the known
defects in Treg cell function in these mice.) The helper effect
of CD40L-sufficient Treg cells was fully titratable (shown in
Figure S2B). Thus, these findings in the nonlymphopenic
Cd40lg/ model confirmed all of the essential findings from
the Tcra/ model.n as above, and draining LNs were analyzed on day 4. GFP and YFP are both
by OVA vaccine containing IFA plus graded amounts of CpG. CD4+ cells were
dye-dilution and intracellular granzyme B.
). See also Figure S1.
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Figure 2. Reprogrammed TregCells Are Functionally Required to Support Early CD8+ TCell Response to aCross-presented Vaccine Antigen
(A–C) T cell-deficient Tcra/ host mice received adoptive transfer of sorted Treg cells or CD4+ non-Treg cells as indicated. Mice were rested for 1–7 days, then
received CFSE-labeled OT-I cells and immunization with OVA+CpG+IFA. Responses were analyzed in draining LNs after 4 days.
(A) Foxp3GFP Treg cells or non-Treg cells (CD4+GFP–) were transferred; controls received no CD4+ cells. Comparison of OT-I cell responses in draining LN.
(B) Treg cells (CD4+CD25+) were sorted from wt B6 or Cd40lg/mice and transferred into Tcra/ hosts (controls received no CD4+ cells), followed by adoptive
transfer of OT-I cells and vaccination with OVA+CpG+IFA. Draining LNs were analyzed for DCs (CD11c+) and OT-I cells (CD8+).
(C) Tcra/mice received Foxp3GFP Treg cells or no Treg cells. A third group received no Treg cells but were treated with anti-CD40 (clone FGK45, 250 mg i.p. on
the day of vaccination and 100 mg i.p. 2 days later). Plots show CFSE-labeled OT-I cells in vaccine-draining LNs on day 4.
(D) CD40L-deficient host model: Cd40lg/ mice received adoptive transfer of CD40L-sufficient Foxp3GFP Treg cells (2–4 3 105 CD4+GFP+) or non-Treg cells
(1 3 106 CD4+GFP–), both congenically marked with Thy1.1. All mice received CFSE-labeled OT-I cells and immunization as above, and response of OT-I cells
and transferred CD4+ cells was analyzed on day 4.
In each panel, data are representative of 3–6 experiments. See also Figure S2.
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Figure 3. Progressive Unresponsiveness to Vaccination Induced by
Established Tumors
C57BL/6 mice were implanted with 1 3 106 B16F10 tumor cells (control mice
received no tumor). After 3–7 days of tumor growth, mice received adoptive
transfer of CFSE-labeled resting pmel-1 cells (sorted CD8+) and gp100+
CpG+IFA vaccine. 4 days later, tumor-draining LNs were analyzed (or
vaccine-draining LN in mice without tumors). Representative of a total of
nine experiments on day 7 and three experiments each on other days.
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They Are Preactivated
The lack of helper activity in the conventional (non-Treg) CD4+
cells was somewhat surprising, because these are the classical
‘‘T helper’’ cells. However, the naive CD4+ repertoire contains an
extremely low frequency of clones specific for a new antigen
(Moon et al., 2007). We hypothesized that the failure of conven-
tional CD4+ cells to provide help in our priming model was due to
the low number of OVA-specific clones. (In contrast, the Treg
cells—with their high frequency of self-reactive TCRs—would
have no such limitation.) To determine whether increasing the
clonal frequency would allow cognate help from conventional
(non-Treg) CD4+ cells, we preimmunized donor mice with OVA
vaccine and boosted themmultiple times to create OVA-specific
memory cells. Figure S2C shows that under these conditions,
the conventional, non-Treg CD4+ cells now became able deliver
help to CD8+ T cells (whereas the same population from naive,
unprimed mice could not). Similarly, if conventional (non-Treg)
CD4+ cells were isolated from TCR-transgenic OT-II mice, which
have a high clonal frequency of OVA-specific CD4+ cells, these
likewise showed good helper activity (Figure S2D). Thus,
conventional (non-Treg) CD4+ cells could deliver help, as
expected, as long as they were preimmunized with cognate
antigen or were present at high clonal frequency. However, in
a normal ‘‘resting’’ CD4+ repertoire, the non-Treg CD4+ cells
showed little spontaneous helper activity for a new antigen.
Indeed, even when non-Treg cells were selectively enriched for
cells with an ‘‘antigen-experienced’’ (CD62Llo) phenotype, non-
Treg cells from (naive) resting hosts still failed to provide any
spontaneous helper activity (Figure S2E). The non-Treg CD4+
population became able to deliver spontaneous help only if
they were first preactivated in vivo by systemic administration
of CpG for 7–10 days (Figure S2E). Thus, whereas both Treg cells
and conventional CD4+ non-Treg cells were able to mediate
help, the unique feature of reprogrammed Treg cells was that
they could provide immediate, spontaneous help for new anti-
gens, without requiring prior preactivation.
Established B16F10 Tumors Induce Progressive
Unresponsiveness to Vaccine
We next evaluated the response to vaccination in mice with
established tumors. This is a very different setting from naive
mice, because established tumors actively inhibit T cell
responses against tumor-associated antigens. We used the
B16F10 melanoma model because B16 tumors are known to
suppress antitumor immune responses (Quezada et al., 2008),
and the B16F10 subline is particularly immunosuppressive
(Shields et al., 2010).
Figure 3 demonstrates the progressive loss of T cell response
to vaccination during B16F10 tumor growth. Mice bearing
tumors of different durations received TCR-transgenic pmel-1
cells (CD8+, recognizing the shared self-tumor antigen gp100)
(Overwijk et al., 2003), then were vaccinated with an altered
peptide ligand (human gp100) in CpG + IFA (Overwijk et al.,
2003). In mice without tumors, this vaccine produced robust
proliferation of pmel-1 cells; however, in mice with day 3 tumors,
response to vaccine was markedly reduced, and by day 7 of
tumor growth, the response to vaccination was essentially lost.
The kinetics of suppression depended on the specific tumorIcell line and the size of the tumor inoculum, but similar unrespon-
siveness was seen with E.G7 lymphoma (not shown), and our
findings are consistent with reports by others (Oizumi et al.,
2008).Tumor-Induced IDO Blocks Treg Cell Reprogramming
We have previously shown that B16 tumors upregulate host
expression of the immunosuppressive enzyme IDO
(Munn et al., 2004). In vitro, IDO can stabilize the suppressive
(regulatory) phenotype of Treg cells and inhibit their reprogram-
ming into helper-like cells (Sharma et al., 2009). Therefore, we
asked whether elevated IDO expression in hosts with estab-
lished B16F10 tumors prevented Treg cells from undergoing
normal reprogramming. Figure 4A (middle column of dot plots)
shows that mice with established tumors displayed markedly
impaired reprogramming of Treg cells after vaccination (seen
as reduced IL-17 and CD40L expression and complete absence
of IL2 and TNFa expression). In contrast, when IDO was blocked
with the IDO-inhibitor drug 1-methyl-D-tryptophan (1MT), then
the same vaccination regimen caused extensive Treg cell
reprogramming (right dot plots). (The figure shows data from
tumor-draining LNs; similar results were also seen in LNs drain-
ing the vaccination site.)
In other studies, reprogramming was seen with both a repre-
sentative Class B and Class C oligonucleotide (Figure S3), and
we have previously shown that extensive reprogramming occurs
subsequent to lentiviral vaccines as well (Sharma et al., 2009);
thus, vaccine-induced Treg cell reprogramming was a general-
ized phenomenon seen in multiple vaccine systems.
The oral 1MT used in Figure 4Awas a systemic inhibitor of IDO.
To more specifically test the hypothesis that IDO directly
affected Treg cells, we asked whether the effect of IDO was
lost when Treg cells lacked the GCN2 kinase signaling pathway.
GCN2 (encoded by the Eif2ak4 gene) senses amino acid depri-
vation, and an intact GCN2 pathway is required in target
T cells in order for IDO to exert many of its effects (Munn et al.,
2005; Sharma et al., 2007). Treg cells were enriched from micemmunity 33, 942–954, December 22, 2010 ª2010 Elsevier Inc. 947
Figure 4. Treg Cell Reprogramming in Tumor-Bearing Hosts Is Antagonized by IDO and Restored by Pharmacologic IDO Inhibitor
(A) Foxp3GFP host mice were implantedwith B16F10 tumors. On day 7 of tumor growth, mice received adoptive transfer of resting pmel-1 cells (sorted CD8+), with
or without gp100+CpG+IFA vaccine. Groups were treated either with continuous 1MT in drinking water (beginning on day 6, 1 day prior to vaccination) or with
vehicle control, as indicated. 4 days after vaccination, tumor-draining LNswere harvested, treatedwith low-dose PMA+ionomycin, and stained as in Figure 1. The
lower set of dot plots show the gated GFP+ (Treg cell) population.
(B) 1 day prior to tumor implantation, Treg cells (CD4+CD25+) were enriched from GCN2-deficient Eif2ak4/ mice or from wt B6 controls and transferred into
congenic Thy1.1+ hosts. B16F10 tumors were then implanted, and 7 days later mice received pmel-1 cells and vaccine as in (A). (None of the mice were treated
with 1MT.) After 4 days, the transferred Treg cells were analyzed in tumor-draining LNs.
(C) Prior to tumor implantation, T cell-deficient Tcra/ hosts received amixture of CD4+ cells, comprising Thy1.2+ Treg cells from Foxp3GFP donors plus congenic
Thy1.1+ non-Treg cells (CD4+GFP–Thy1.1+). All mice then received B16F10 tumors, and 7 days later were treated with pmel-1 cells and vaccine, with or without
oral 1MT as indicated. 4 days after vaccination, tumor-draining LNs were analyzed for transferred Treg cell and non-Treg cell populations, gated separately on
Thy1 allotype.
Each panel is representative of 3–6 experiments. See also Figure S3.
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wt B6 controls (both on the Thy1.2 background) and transferred
into congenic Thy1.1+ hosts (Figure 4B). Mice then received948 Immunity 33, 942–954, December 22, 2010 ª2010 Elsevier Inc.tumors and were vaccinated 7 days later but were not treated
with 1MT. Under these conditions (IDO active), there was little
detectable reprogramming of the transferred wt Treg cell cohort,
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Eif2ak4/ mice were resistant to the effects of IDO and under-
went normal reprogramming after vaccination, despite the pres-
ence of tumor, and without the need for 1MT.
Taken together, these data indicated that established tumors
progressively created a milieu in tumor-bearing hosts in which
the normal, vaccine-induced reprogramming of Treg cells was
suppressed and could no longer occur. This inhibition of reprog-
ramming was mediated by tumor-induced IDO, as shown both
by a pharmacologic IDO inhibitor and via IDO-resistant
Eif2ak4/ Treg cells.
Mature Pre-existing Treg Cells Undergo
Vaccine-Induced Reprogramming
It was formally possible that the cytokine-expressing Foxp3-
GFP+ cells seen in Figure 4A might actually arise from naive
CD4+ cells that merely upregulated Foxp3 de novo (rather than
deriving from mature Treg cells that had converted). To defini-
tively establish whether the cells that we observed were derived
from mature, pre-existing Foxp3+ Treg cells, we cotransferred
marked populations of Treg cells and non-Treg CD4+ cells into
the same Tcra/ hosts (Figure 4C). The Treg cell subset was
sorted from Foxp3GFP donors (Thy1.2+) and the non-Treg cell
subset (CD4+GFP–) from congenic Foxp3GFP-Thy1.1 donors. Cells
were mixed in the original ratio (1:5) and transferred into Tcra/
hosts; then all mice were inoculated with B16F10 tumors, and
7 days later received pmel-1 cells and gp100 vaccination, with
or without 1MT. Figure 4C shows that after vaccination, all of
the CD4+ cells in tumor-draining LNs expressing proinflamma-
tory cytokines and CD40L derived exclusively from the original
Treg cell population, whereas the non-Treg cell population
remained quiescent and contributed none of these activated
helper cells.
Thus, in our model of resting CD4+ cells acutely exposed to
antitumor vaccination in a tumor-bearing host, it was the highly
responsive Treg cell population that accounted for virtually all
of the vaccine-induced helper cell response, during the initial
4-day window on which we were focused. Of note, however,
the Treg cells were not able to contribute this inflammatory
response unless tumor-induced IDO was first blocked by 1MT
administration.
Reprogrammed Treg Cells Support CD8+ T Cell
Response to Antitumor Vaccine
We next asked whether blocking IDO also restored the CD8+
T cell responses that were progressively lost in hosts with estab-
lished tumors (see Figure 3). Figure 5A shows that when tumor-
bearing mice were treated with 1MT at the time of vaccination,
then resting pmel-1 cells in tumor-draining LNs once again
became able to divide in response to vaccination and could up-
regulate granzyme B and the chemokine receptor CXCR3 (a
functionally importantmarker of CD8+ T cell maturation, because
it is required for homing to sites of inflammation). Within the
tumor itself, activated, proliferating pmel-1 cells were found in
mice treated with 1MT during vaccination, but not in mice
without 1MT. As a proxy for functional antitumor effect, tumors
were dissected at the end of the experiment (day 11) and their
size measured, as shown in the bar graph. This was not
a measure of long-term tumor regression, because all tumorsIeventually grew back after a single dose of vaccine; however,
the rapid and significant reduction in tumor size compared to
controls served as useful experimental confirmation that the
proliferating, granzyme B-expressing pmel-1 cells were associ-
ated with biologically relevant antitumor activity. In other confir-
matory experiments (data not shown) similar effects of 1MT on
vaccination were seen in the E.G7 tumor system as well.
We next asked whether the beneficial effect of 1MT on CD8+
T cell responses was specifically due to its ability to restore
Treg cell reprogramming. The pmel-1 system was informative
in this regard, because pmel-1 cells are known to require CD4+
T cell help in order to achieve optimal antitumor efficacy (Antony
et al., 2005). In Figure 5B, Tcra/ host mice were preloaded with
different CD4+ populations (either sorted Foxp3GFP Treg cells,
non-Treg CD4+ cells, or no CD4+ cells). All mice were implanted
with B16F10 tumors, and on day 7 received pmel-1 cells and
gp100 vaccine, with or without 1MT. In the absence of all
CD4+ cells, pmel-1 cells showed poor response to vaccination,
despite 1MT administration. Adoptive transfer of non-Treg
CD4+ cells provided no detectable help for pmel-1 cells, even
with 1MT. Only the Treg cell fraction supported proliferation
of pmel-1 cells, granzyme B upregulation, and antitumor
effect in the presence of 1MT (Figure 5B, third dot plot). The
beneficial effects of Treg cells was lost if 1MT was omitted (Fig-
ure 5B, last dot plot), consistent with the fact that Treg cells could
not undergo normal reprogramming when IDO was active (as
shown in Figure 4A). Thus, the beneficial effects of 1MT on anti-
tumor vaccination appeared heavily dependent on its ability to
restore Treg cell reprogramming and the helper activity they
provided.
To further test this hypothesis, we asked whether Treg cells
that could undergo reprogramming even in the presence of
IDO (i.e., GCN2-deficient Treg cells from Eif2ak4/ mice, see
Figure 4B) would be able to bypass the need for 1MT treatment.
C57BL/6 host mice received a cohort of either Eif2ak4/ Treg
cells or wt control Treg cells, then tumors were implanted and
established tumors treated on day 7 with vaccination and
pmel-1 cells. Figure 5C shows that the presence of Eif2ak4/
Treg cells provided spontaneous help for pmel-1 T cells, even
in the face of established tumors, without the need for 1MT treat-
ment. The help provided spontaneously by GCN2-deficient Treg
cells (without 1MT) was comparable to wild-type Treg cells
treated with 1MT. (There was also a further benefit of adding
1MT to the Eif2ak4/ Treg cells, which was expected because
the pmel-1 cells and all host cells were still susceptible to IDO.)
Taken together, the preceding data suggested that a critical
immunologic defect imposed by tumor-induced IDO was the
suppression of normal Treg cell reprogramming. This implied
that Treg cells might actually play a beneficial role in tumor
immunotherapy (if they could be reprogrammed); yet this
seemed counterintuitive given that Treg cell depletion has
been used to enhance antitumor immune responses. (Although
in this regard it is not clear that Treg cell depletion offers benefit
once tumors become established) (Quezada et al., 2008).
To resolve this, we rigorously depleted Treg cells from mice
with established tumors by using a diphtheria-toxin receptor
driven by the Foxp3 promoter, as shown in Figure S4. This
allowed inducible depletion of >95% of Treg cells. The effect
of this rigorous Treg cell ablation was a modest enhancementmmunity 33, 942–954, December 22, 2010 ª2010 Elsevier Inc. 949
Figure 5. Inhibition of IDO Enhances Efficacy of Antitumor Vaccination by Restoring Help from Reprogrammed Treg Cells
(A) C57BL/6 mice with day 7 established B16F10 tumors received resting CFSE-labeled pmel-1 cells and vaccination with gp100+CpG+IFA, with or without 1MT
in drinking water as shown. 4 days later, gated pmel-1 cells (Thy1.1+) were analyzed in tumor-draining LN and disaggregated tumor. Representative of 6 exper-
imentswith tumors and 11 experimentswith tumor-draining LNs. Tumor size (product of orthogonal diameters) is shown after dissection at necropsy (day 11). *p <
0.01 by t test (n = 16 tumors in 8 separate experiments; error bars show SD).
(B) Tcra/ hosts received preadoptive transfer of Foxp3GFP Treg cells, or CD4+GFP– non-Treg cells, or no CD4+ cells, as indicated. Mice were then implanted
with B16F10 tumors, and on day 7 received pmel-1 cells and gp100+CpG+IFA vaccine, with or without 1MT as shown. 4 days later, pmel-1 cells were analyzed in
tumor-draining LN, and tumor size was measured at necropsy. Pooled data from 13 experiments (number of tumors indicated in the bar graph, *p < 0.05 by
ANOVA; error bars show SD).
(C) Treg cells (CD4+CD25+) were sorted from GCN2-deficient Eif2ak4/mice or wt control donors and 23 105 cells were transferred into wt (C57BL/6) hosts. All
mice were then implantedwith B16F10 tumors, and on day 7 received pmel-1 cells, gp100+CpG+IFA vaccination, and 1MT as shown. CFSE-labeled pmel-1 cells
were measured in TDLNs on day 11. Representative of three experiments; *p < .05 by ANOVA; error bars show SD.
See also Figure S4.
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Figure 6. Helper Activity of Reprogrammed Treg Cells in Tumor-Bearing Hosts Is Mediated via CD40L
(A) C57BL/6 orCd40lg/ hosts were implanted with B16F10 tumors, then on day 7 received pmel-1 cells and gp100+CpG+IFA vaccine, with or without oral 1MT
as indicated. 4 days later, DCs (CD11c+) were analyzed in tumor-draining LNs. Control mice received no tumor and no treatment.
(B) Tcra/ mice received pretransfer of a mixed CD4+ population comprising 1 3 106 non-Treg cells (CD4+GFP– cells from Foxp3GFP mice) plus 2 3 105 Treg
cells (enriched as CD4+CD25+) from either C57BL/6 or Cd40lg/ mice. All mice were implanted with B16F10 tumors, and on day 7 received pmel-1 cells and
gp100+CpG+IFA vaccine, with or without 1MT as shown. 4 days later, pmel-1 cells were analyzed in tumor-draining LNs, and tumor size was measured at
necropsy (*p < 0.05 by ANOVA; n per group shown in the figure; error bars show SD).
(C) Tcra/mice received pretransfer of Treg cells (CD4+CD25+) from either wt orCd40lg/mice, as shown. All micewere implanted with B16F10 tumors, and on
day 7 received pmel-1 cells and gp100+CpG+IFA vaccine, with or without 1MT as indicated. One group also received activating anti-CD40 (clone FGK45, as in
Figure 2C).
In each panel, data are representative of 3–5 experiments. See also Figure S5.
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1MT, but with a complete loss of the beneficial effects of 1MT
(which, as we showed above, was dependent on Treg cell
conversion). Thus, complete ablation of Treg cells did indeed
confer some benefit, but it came at the cost of losing the helper
effect of reprogrammed Treg cells conferred by 1MT.
Helper Activity of Reprogrammed Treg Cells
for Antitumor Responses Requires CD40L
We knew from Figure 2B that reprogrammed Treg cells could
activate DCs in aCD40L-dependent fashion.We therefore asked
whether CD40L was also required for DC activation when tumor-Ibearing mice were treated with vaccine+1MT. In resting control
mice (without tumors), DCs expressed low basal levels of
CD80 and CD86 (Figure 6A, first set of histograms). In mice
with established tumors, DC activation was almost completely
suppressed after vaccination (Figure 6A, second set of histo-
grams). However, if mice were treated with 1MT at the time of
vaccination, then DCs expressed high amounts of CD80 and
CD86 (Figure 6A, third set of histograms). The ability of 1MT to
restore expression of CD80 and CD86 was entirely lost in host
mice lacking CD40L (Figure 6A, fourth set of histograms), sug-
gesting that CD40L was an important downstream mediator of
DC activation by 1MT+vaccination.mmunity 33, 942–954, December 22, 2010 ª2010 Elsevier Inc. 951
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expression was specifically on reprogrammed Treg cells.
Tcra/ hosts were preloaded with a mixture of Treg cells plus
non-Treg CD4+ cells (Figure 6B). In half of themice, the Treg cells
were taken from Cd40lg/ donors, while the other half received
CD40L-sufficient (wt) Treg cells. In all mice, the non-Treg cell
fraction (GFP–) was taken from Foxp3GFP mice with intact
CD40L. Thus, after reconstitution, all host cells and all non-
Treg CD4+ T cells had intact CD40L, and the groups differed
only in whether the Treg cell population could express CD40L.
All mice then received pmel-1 cells and gp100 vaccination,
with or without 1MT as shown. Figure 6B shows that only those
mice receiving CD40L-sufficient Treg cells—but not mice
receiving Cd40lg/ Treg cells—were able to support full CD8+
T cell responses in the presence of 1MT (proliferation, granzyme
B expression, and antitumor activity). Thus, CD40L was required
for CD4 helper activity in this model, and the relevant source of
CD40L was specifically derived only from the Treg cell popula-
tion. (In these studies, the CD4+CD25+ sorted Treg cell prepara-
tion contained a small number of contaminating non-Treg cells;
however, this was irrelevant because all mice already received
a large excess of CD40L-competent non-Treg cells, with no
effect.)
Figure 6C shows that the defect in helper activity of Cd40lg/
Treg cells could be substantially rescued by treating mice with
a cross-linking antibody against CD40. The antibody was not
as effective as authentic CD40L, but it could restore both prolif-
eration and granzyme B expression, thus supporting a direct
mechanistic contribution of the CD40 pathway.
Finally, Figure S5 confirms the preceding results in a second
model, asking whether CD40L expression specifically on Treg
cells could restore the defective antitumor helper activity seen
in Cd40lg/ hosts. In Cd40lg/ hosts with established tumors,
adoptively transferred wild-type Treg cells underwent successful
vaccine-induced reprogramming when host mice were treated
with 1MT, and this restored the ability of the CD40L-deficient
hosts to support antitumor CD8+ T cell responses. Only the
Treg cell fraction (but not the non-Treg CD4+ cell fraction) was
able to restore defective helper activity in Cd40lg/ hosts with
tumors, and Treg cell reprogramming could occur only if IDO
was blocked with 1MT.
Thus, taken together, our data suggested that one key contri-
bution of reprogrammed Treg cells to antitumor vaccination was
the provision of CD40L-mediated signals. If tumor-induced IDO
was active, then Treg cells were prevented from undergoing
vaccine-induced reprogramming and could not provide this
critical signal. However, if IDO was blocked by 1MT then Treg
cells could reprogram, CD40L was expressed, and response
to antitumor vaccination was enhanced.
DISCUSSION
By using a standard vaccine model, we show that in certain
settings reprogrammed Treg cells can be required in order to
support the initial (priming) response of CD8+ T cells to
a cross-presented antigen. Conventional (non-Treg) CD4+ cells
could supply similar help if theywere already preactivated or pre-
immunized. But in a resting mouse exposed for the first time to
a new antigen, it was the reprogrammed Treg cells that provided952 Immunity 33, 942–954, December 22, 2010 ª2010 Elsevier Inc.virtually all of the helper activity to support the initial cross-
presentation to CD8+ cells.
In our system, Treg cells became activated within hours of
vaccination, and reprogramming was driven by adjuvant-
induced inflammatory signals (CpG, MyD88, IL-6). Traditionally,
these early events after vaccination have been considered
strictly the province of the innate immune system. Our findings
do not conflict with this model, but rather identify reprogrammed
Treg cells as an integral downstream component of this ‘‘innate’’
inflammatory cascade. We show that Treg cells, via their ability
to rapidly upregulate CD40L, can act as a mechanistic interme-
diate linking vaccine-induced inflammation with CD40-mediated
licensing of DCs.
Our experiments were performed with a CpG-based vaccine,
but we hypothesize that the phenomenon may be broadly rele-
vant to any context inwhich a newantigen is encounteredwithout
a large, pre-existing cohort of antigen-specific conventional
helper cells (i.e., any priming exposure to a new antigen). Under
these conditions, we hypothesize that Treg cells constitute a crit-
ically important pool of ‘‘preformed’’ helper cells. This role for
Treg cells addresses a long-standing paradox in adaptive immu-
nity (Cohn, 2009): namely, how do helper-dependent CD8+
immune responses ever get started? The precursor frequency
of naive CD4+ cells against a new antigen is extremely low
(Moon et al., 2007), and clonal expansion takes many days. Yet
the initial presentation of ‘‘helper-dependent’’ antigens to CD8+
T cells implicitly assumes that CD4+ cells are available from the
start in order to license the DCs (Bennett et al., 1997; Schoen-
berger et al., 1998). Where do these early helper cells come
from?We now show that a large fraction of Treg cells are consti-
tutively ready to undergo rapid conversion into helper cells in
response to innate inflammation and that, under certain condi-
tions, help from these cells can be indispensable to support initial
CD8+ T cell responses to a new antigen. Thus, although classical
non-Treg CD4+ cells are sufficient to provide help under most
circumstances, in the specialized case of a new antigen encoun-
tered by a naive host, Treg cells can play an unexpectedly critical
role as helper cells. This may help explain, in part, the otherwise
paradoxical observation that mice in which the Foxp3 lineage is
inducibly ablated become unable to mount a protective early
immune response to a new viral infection (Lund et al., 2008).
Mechanistically, we hypothesize that local production of IL-6
is a key signal that instructs Treg cells when to reprogram for
helper function. Earlier studies implicated IL-6 as a mechanism
by which TLR-ligands could ‘‘turn off’’ the suppressive activity
of Treg cells (Pasare andMedzhitov, 2003). IL-6 is known to drive
Treg cell reprogramming in vitro (Yang et al., 2008), andwe found
that Il6/ mice failed to undergo normal reprogramming in our
system. We have also shown that IL-6 production by DCs can
be directly suppressed by IDO in an autocrine or paracrine
fashion, via IDO-induced activation of the GCN2 pathways in
the DCs (Sharma et al., 2009). Now we demonstrate that IDO
can also act directly on the Treg cells themselves via activation
of their own endogenous GCN2 pathway, to inhibit reprogram-
ming. We have previously shown that GCN2 is an important
pathway by which IDO activates Treg cells for enhanced
suppression (Sharma et al., 2007), and others have shown that
GCN2 suppresses Th17 cell lineage differentiation (Sundrud
et al., 2009). Thus, IDO acts to inhibit Treg cell reprogramming
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directly, via the GCN2 pathway in Treg cells.
In mice with established B16F10 tumors, the net effect of the
IDO-GCN2 pathway was to dominantly inhibit Treg cell reprog-
ramming after vaccination. For these studies, we chose the
B16F10 subline because it is highly immunosuppressive (Shields
et al., 2010) and it is also a potent inducer of IDO (Sharma et al.,
2007). In thismodel, IDOsuppressed the normal vaccine-induced
Treg cell conversion, which proved to be a major mechanism
contributing to the inability of vaccination to prime antitumor
T cells. This inhibition of Treg cell reprogramming was not an
absolute defect; it could be bypassed by providing cognate
tumor-specific CD4+ help (e.g., TCR-transgenic OT-II cells), and
it is certainly not the only defect in tumor-bearing hosts. Neverthe-
less, IDO-induced suppression of Treg cell reprogramming
proved to be a critical and previously unappreciated checkpoint
inour tumorsystem.Moreover, it couldbe targetedwithaclinically
relevant drug (1-methyl-D-tryptophan, 1MT), which is currently in
Phase I clinical trials. Granted, not all tumors may be so heavily
dependent on IDO as our B16F10 model, and we examined only
a single, short-term priming vaccination (in which conventional
helper memory cells were not yet available); nonetheless our
model serves to make the mechanistic point that, in at least
some settings, it may actually be more beneficial to reprogram
Treg cells in situ than to rigorously deplete them.
Additional studies will be required to elucidate the antigen
specificity of the reprogrammed Treg cells. In general, Foxp3+
Treg cells are thought to include many TCRs that recognize
self peptides (Fisson et al., 2003). We hypothesize that this
recognition of ubiquitously expressed self antigens allows a large
pool of Treg cells to interact spontaneously with APCs during
vaccination, thereby allowing delivery of help without requiring
cognate specificity for the new (vaccine) antigen.
Taken together, our findings suggest a previously unappreci-
ated helper role for cells in the Foxp3+ Treg cell lineage. The help
provided by converted Treg cells was not in itself different from
that provided by conventional CD4+ cells; rather, Treg cells were
distinguished by their unique ability to deliver help immediately
and spontaneously, without needing prior priming or
preactivation. It has long been recognized that Treg cells are
unusual in that many Treg cells appear to circulate in a constitu-
tively activated state (Fisson et al., 2003). Resting Treg cells
respond much more rapidly to inflammatory signals than do
conventional CD4+ cells (O’Gorman et al., 2009). We propose
that this rapid-response, ‘‘hair-trigger’’ capability may in fact be
the fundamental, distinguishing attribute of the Foxp3+ lineage.
Wehypothesize thatFoxp3 lineagecells representapoolofconsti-
tutively primed ‘‘first responder’’ cells: capable of rapid suppres-
sion where that is appropriate, but also able (when directed by
the innate immune system) to supply potent helper activity during
the early phases of the immune response, at a time when conven-
tional antigen-specific T helper cells are not yet available.EXPERIMENTAL PROCEDURES
Reagents and Mice
Details of reagents and mouse strains are given in Supplemental Information.
Animal studies were approved by the Institutional Animal Care and Use
Committee of the Medical College of Georgia.ITumors
B16F10 cell line was obtained from ATCC. Tumor implantation was performed
as described (Sharma et al., 2007) with 1 3 106 cells in order to ensure rapid
tumor growth and immune suppression. Tumor area was measured at
necropsy on day 11 as the product of orthogonal diameters after dissection.Vaccines
CpG-1826 was synthesized as described in Supplemental Experimental
Procedures. Human gp10025-33 (KVPRNQDWL) was synthesized by Southern
Biotechnology (Overwijk et al., 2003). Whole OVA protein was obtained from
Sigma (catalog #A-5503). Vaccines were prepared by emulsifying 100 mg of
OVA protein or 25 mg gp100 peptide with 50 mg CpG-1826 in incomplete
Freund’s adjuvant (Sigma F-5506) and administered in the footpad.Adoptive Transfer
For CD8+ T cell transfers, OT-I or pmel-1 spleen cells were enriched for CD8+
cells by magnetic bead isolation (Miltenyi Biotech), labeled with CFSE as
described (Munn et al., 2005), and 23 106 cells injected i.v. All CD4+ transfers
were sorted from spleens of donor mice by MoFlo cell-sorter with doublet
discrimination (>95% post-sort purity). Treg cells (usually 23 105 cells unless
otherwise indicated) or non-Treg cells (CD4+GFP–, 13 106 cells) were injected
i.v. For Cd40lg/ and Eif2ak4/ donors, Treg cells were enriched by sorting
for CD4+CD25+ cells (>90% Foxp3 cells by intracellular staining). All experi-
ments with the non-Treg cell fraction were always sorted based on Foxp3GFP
fluorescence, to rigorously exclude any Treg cells.FACS Staining
Details of staining and the low-dose PMA activation protocol are given in
Supplemental Experimental Procedures. LNs were disaggregated by passage
through 40 mmmesh. Tumors were disaggregated as described (Sharma et al.,
2009).Statistical Analysis
Multiple treatment groups were compared by ANOVA with Tukey’s HSD test.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and five figures and can be found with this article online at doi:10.1016/j.
immuni.2010.11.022.ACKNOWLEDGMENTS
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